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Introduction: The emergency department (ED) plays a critical role in the management
of life-threatening infection. Prior data suggest that ED vancomycin dosing is frequently
inappropriate.The objective is to assess the impact of an electronic medical record (EMR)
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intervention designed to improve vancomycin dosing accuracy, on vancomycin dosing and clinical
outcomes in critically ill ED patients.
Methods: Retrospective before-after cohort study of all patients (n=278) treated with vancomycin
in a 60,000-visit Midwestern academic ED (March 2008 and April 2011) and admitted to an
intensive care unit. The primary outcome was the proportion of vancomycin doses defined as
“appropriate” based on recorded actual body weight. We also evaluated secondary outcomes of
mortality and length of stay.
Results: The EMR dose calculation tool was associated with an increase in mean vancomycin
dose ([14.1±5.0] vs. [16.5±5.7] mg/kg, p<0.001) and a 10.3% absolute improvement in first-dose
appropriateness (34.3% vs. 24.0%, p=0.07). After controlling for age, gender, methicillin-resistant
staphylococcus aureus (MRSA) infection, and Acute Physiology and Chronic Health Evaluation II
(APACHE-II) score, 28-day in-hospital mortality (odds ratio OR 1.72; 95% CI [0.76-3.88], p=0.12)
was not affected.
Conclusion: A computerized decision-support tool is associated with an increase in mean
vancomycin dose in critically ill ED patients, but not with a statistically significant increase in
therapeutic vancomycin doses. The impact of decision-support tools should be further explored to
optimize compliance with accepted antibiotic guidelines and to potentially affect clinical outcome.
Supporting material:
Revised order in EMR. Providers see the recommended dose as the default value, and the
computer calculates a recommended first dose based on 20 mg/kg actual body weight with
maximum dose 2 grams.
Pre and Post intervention vancomycin administration and eligible patients for analysis flow
diagram
Appropriateness of Vancomycin Dose by Patient Weight.
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Introduction: The emergency department (ED) plays a critical role in the management of life-
threatening infection. Prior data suggest that ED vancomycin dosing is frequently inappropriate.
The objective is to assess the impact of an electronic medical record (EMR) intervention designed 
to improve vancomycin dosing accuracy, on vancomycin dosing and clinical outcomes in critically 
ill ED patients.
Methods: Retrospective before-after cohort study of all patients (n=278) treated with vancomycin in 
a 60,000-visit Midwestern academic ED (March 2008 and April 2011) and admitted to an intensive 
care unit. The primary outcome was the proportion of vancomycin doses defined as “appropriate” 
based on recorded actual body weight. We also evaluated secondary outcomes of mortality and 
length of stay.
Results: The EMR dose calculation tool was associated with an increase in mean vancomycin 
dose ([14.1±5.0] vs. [16.5±5.7] mg/kg, p<0.001) and a 10.3% absolute improvement in first-dose 
appropriateness (34.3% vs. 24.0%, p=0.07). After controlling for age, gender, methicillin-resistant 
staphylococcus aureus infection, and Acute Physiology and Chronic Health Evaluation II score, 28-
day in-hospital mortality (odds ratio OR 1.72; 95% CI [0.76-3.88], p=0.12) was not affected.
Conclusion: A computerized decision-support tool is associated with an increase in mean 
vancomycin dose in critically ill ED patients, but not with a statistically significant increase in 
therapeutic vancomycin doses. The impact of decision-support tools should be further explored to 
optimize compliance with accepted antibiotic guidelines and to potentially affect clinical outcome.
[West J Emerg Med. 2015;16(4):557–564.]
University of Iowa Hospitals and Clinics, Department of Emergency Medicine, Iowa 
City, Iowa
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Vancomycin is a glycopeptide antibiotic that exhibits 
time-dependent killing. It has been used for more than five 
decades to treat resistant organisms, such as methicillin-
resistant Staphylococcus aureus (MRSA), and in the empiric 
treatment for severe sepsis and septic shock. Efficacy is 
often predicted by the ratio of the area under the antibiotic 
concentration curve and the minimum inhibitory concentration 
of the infecting pathogen (AUC/MIC ratio). An AUC/MIC 
ratio of ≥400 with trough serum concentrations of 15-20mg/L 
are recommended to achieve clinical effectiveness and 
limit the development of resistant microorganisms.1 MRSA 
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vancomycin treatment failures are occurring with increasing 
frequency, and vancomycin-intermediate Staphylococcus 
aureus (VISA) has emerged as a leading cause of vancomycin 
failures and poor clinical outcomes.2-3 
Inappropriate vancomycin dosing is associated with 
the emergence of VISA.4-6 Conventional dosing practices 
initiate vancomycin at 1000mg every 12 hours.7 Due to 
the association of conventional dosing and subtherapeutic 
vancomycin trough levels, however, current guidelines 
advocate for weight-based dosing algorithms.1,8 
The emergency department (ED) plays a critical role in 
the management of life-threatening infection.9 There is also 
an increased awareness of the ED’s role in antimicrobial 
initiation, with an increased interest in antibiotic stewardship 
beginning in the ED.10 ED antibiotic initiatives include 
both appropriate usage and timely administration. Prior 
data suggest that ED dosing of vancomycin is frequently 
inappropriate, yet vancomycin administered in the ED is 
often continued into the inpatient course.7,11 This suggests 
that the ED is highly influential on overall antibiotic therapy, 
regardless of dosing or indication appropriateness.7 This 
practice pattern has the potential for developing antibiotic 
resistance, as organisms such as VISA are invariably 
associated with vancomycin exposure and subtherapeutic 
dosing strategies.4 
Appropriate antibiotic selection and dose optimization is 
a prime determinant of outcome in critically ill patients.12 ED 
clinical pharmacists improve appropriate antibiotic dosing, 
yet fewer than 5% of EDs have an ED-based pharmacist.10,13 
Therefore, an electronic medical record (EMR) based 
antibiotic stewardship strategy could be a generalizable 
intervention with a measurable effect on antibiotic selection 
and dosing across many EDs in the community. 
The primary objective of this analysis was to assess 
the impact of an EMR intervention on vancomycin dosing 
accuracy in critically ill ED patients. We hypothesized that an 
EMR intervention would be associated with improvement in 
vancomycin dosing accuracy. Secondary objectives were to 
assess the impact of vancomycin dosing on mortality, hospital 
length of stay, acute kidney injury, and the impact of obesity 
on vancomycin dosing accuracy.
METHODS
Patients and Setting 
This study was a retrospective before-after cohort study 
(March 2008–May 2009 [before] and November 2009–April 
2011 [after]) conducted in the ED of a Midwestern academic 
Level I trauma center with an annual ED census of 60,000 
patient visits. 
Intervention
We included all patients treated with vancomycin in 
the ED and admitted to an intensive care unit. For patients 
who received vancomycin on multiple ED visits during the 
study period (2%), only the first visit was included in the 
analysis. The post-intervention period began after weight-
based vancomycin dosing guidance was incorporated into 
computerized physician order entry (CPOE) to correspond 
to updated guidelines from the Infectious Diseases Society 
of America in 2009.1,14 The EMR intervention included 
an automatic dose calculation tool included in the CPOE 
order, and an educational campaign (e-mail notification to 
all EM staff and a presentation by a research team member 
to EM residents and attending physicians) accompanied the 
rollout. The automatic dose calculation tool recommended 
a vancomycin dose of 20mg/kg actual body weight (as 
recorded in the medical record). The calculated dose was 
rounded to the nearest 250mg and did not recommend 
greater than 2 gram in a single dose (Figure 1). A six-month 
run-in period was excluded from analysis a priori to assure 
that all providers had time to acclimate themselves to the 
new automatic dose calculation tool.
Figure 1. Revised order in EMR. Providers see the recommended dose based on the computer calculation. The computer 
recommended first dose is 20mg/kg actual body weight with maximum dose 2 grams.
EMR, electronic medical record; IDSA, Infectious Diseases Society of America; UHC, University Health System Consortium
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Data Abstraction
We abstracted vancomycin dosing and clinical variables 
from the EMR using both database query and manual data 
collection by two trained data abstractors (KD, BP). The two 
data abstractors were blinded to the study hypothesis and 
received formal training in proper data abstraction techniques. 
After data abstraction, 15% of charts were randomly selected 
for review by a third independent investigator (BAF) to 
validate data accuracy and abstraction techniques. We defined 
all variables a priori and recorded them in an electronic 
database for analysis. 
Definitions
Appropriate vancomycin dose was defined as 15-20mg/
kg in accordance with guideline recommendations.1 We 
based obesity categorization on the definitions by the World 
Health Organization as underweight (body mass index (BMI) 
<18.5), normal (18.5-24.99), overweight (25.0-29.99) and 
obese (≥30).15 Mortality was assessed at 28 days after hospital 
admission. Subjects discharged alive before 28 days were 
coded as alive. We defined acute kidney injury as increase 
in serum creatinine by 0.3mg/dL within 48 hours or increase 
to 1.5 times baseline.16 We calculated Acute Physiology and 
Chronic Health Evaluation II (APACHE-II) scores based on 
clinical data collected within 24 hours of hospital admission. 
Parameters not recorded were imputed to be normal for the 
purposes of APACHE-II calculation. Vancomycin levels were 
collected during each patient’s hospital stay. 
Outcomes 
The primary outcome was the proportion of vancomycin 
doses defined as “appropriate” based on recorded actual body 
weight. Secondary outcomes included 28-day in-hospital 
mortality, hospital length of stay and acute kidney injury 
(safety outcome). We also measured the impact of obesity 
and the sustained effect of the intervention (stratified in 
four-month intervals). Overweight and obese patients who 
received the maximum dose of 2 gram were categorized in the 
“appropriate” group even though the calculator recommended 
larger doses based on the actual weight.
We conducted univariate analysis using t-test, chi-
squared test, or ANOVA, as appropriate. Multivariable 
logistic regression analysis was used to estimate the effect 
of the EMR intervention on 28-day in-hospital mortality, 
controlling for potentially confounding covariates (age, 
sex, MRSA, BMI, APACHE II score, acute kidney injury, 
vasopressor administration, mechanical ventilation and history 
of hemodialysis). We prespecified variables included in the 
model based on a priori knowledge and defined a statistical 
threshold of p<0.20. Collinearity and statistical interactions 
were measured. All tests were two-tailed and a p-value <0.05 
was considered statistically significant. We conducted all 
analyses using SAS® software (version 9.3, SAS System 
for Microsoft, SAS Institute Inc., Cary, NC, USA). The 
institutional review board approved the study protocol. 
RESULTS
We included 278 subjects in the study (Figure 2).17 
Baseline characteristics are shown in Table 1. Mean 
vancomycin dose increased after the intervention ([14.1±5.0] 
vs. [16.5±5.7]mg/kg, p<0.001). First-dose appropriateness 
increased from 24.0% to 34.3%, p=0.07. Overall, 30.6% 
EMR intervention
Total Before After p-value
Total, n(%) 278 100 (36.0) 178 (64.0)
Age, y (SD) 57.2 (17.7) 57.5 (17.5) 57.1 (17.8) 0.85
Male, n(%) 172 (61.9) 58 (58.0) 114 (64.0) 0.32
BMI, kg/m2 (SD) 30.1 (13.1) 31.9 (18.8) 29.1 (9.0) 0.18
APACHE II, score (SD) 17.7 (5.3) 17.8 (5.4) 17.6 (5.2) 0.84
Vancomycin dosing
Total, mean (SD) 1253.6 (381.2) 1115 (283) 1331.5 (407) <0.0001
mg/kg, mean (SD) 15.7 (5.6) 14.1 (5.0) 16.5 (5.7) 0.0003
Patients given 1 gram, n(%) 166 (59.7) 84 (84.0) 92 (51.7) <0.0001
Appropriate dose, n(%) 85 (30.6) 24 (24.0) 61 (34.3) 0.0745
MRSA in culture, n(%) 29 (10.4) 5 (5.0) 24 0.03
Acute kidney injury, n(%) 90 (32.4) 34 (34.0) 56 0.66
28 day in-hospital mortality, n(%) 40 10 (10.0) 30 0.12
Table 1. Patient demographics, outcomes and vancomycin dosing before and after an electronic medical record intervention.
EMR, electronic medical record; APACHE, acute physiology and chronic health evaluation; MRSA, methicillin-resistant Staphylococcus 
aureus; BMI, body mass index
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of patients received an appropriate dose (Table 2). The 
proportion of patients receiving a dose of 1g decreased (84% 
vs. 52%, p<0.001). Vancomycin trough levels were obtained 
in 157 patients (56%), and median trough levels did not 
change during the study period (13.3, IQR [10.6-22.4]) vs. 
13.8, IQR [9.4-18.3], p=0.59)
Twenty-eight day mortality (10.0% vs. 16.9%, p=0.12) 
did not change with the intervention. In univariate analysis, 
mortality was not associated with the intervention period 
(Table 3). Using multivariable logistic regression to adjust 
for age, sex, MRSA infection status, and APACHE-II, 28-
day mortality was not associated with the EMR intervention 
(adjusted odds ratio 1.72 [0.76-3.88], p=0.12). The 
intervention did not significantly increase the risk of acute 
kidney injury in the post intervention group (34.0% vs. 31.5%, 
p=0.66). The appropriateness of the vancomycin dose did not 
have a significant effect on hospital length of stay for the pre- 
and post-intervention groups (Table 2).
Obesity had a significant effect on the appropriateness of 
vancomycin dosing (Figure 3). Overweight (55.2% vs. 34.1%) 
and obese (63.6% vs. 34.1%) subjects were more likely to be 
underdosed (p<0.0001), and no underweight patients were 
underdosed. Underweight patients were more like to receive 
an inappropriately high dose than the normal weight patients 
(72.7% vs. 28.6%, p<0.0001).
The prevalence of MRSA identified as an infectious agent 
from a blood culture or bronchoalveolar lavage increased 
between study periods from 5.0% to 13.5% (p=0.03). Among 
subjects without MRSA, neither inappropriately low nor high 
doses were associated with survival (Table 3).
 
DISCUSSION
As a recommended therapy for critically ill patients with 
life-threatening infection, vancomycin is frequently administered 
in the ED. Although other investigators have examined the role 
of vancomycin dosing on clinical outcomes, our study evaluated 
systematically the effect of an EMR intervention on the clinical 
outcome of patients admitted from the ED to an intensive care 
unit. This is an important finding because it highlights both the 
role of quality improvement initiatives and their unintended 
consequences on clinical outcomes. 
In our cohort, the EMR intervention increased the 
dose of vancomycin (14.1±5.0mg/kg vs. 16.5±5.7mg/
kg, p<0.0001). The increase in the mean vancomycin dose 
was relatively small; however, the proportion of patients 
who received a dose recommended by Infectious Diseases 







Age, y (SD) 60.9 (16.1) 54.8 (16.8) 51.8 (20.7) 0.0015
Male, n(%) 93 (67.4) 41 (48.2) 38 (69.1) 0.0078
BMI, kg/m2 (SD) 32.9 (12.9) 28.3 (9.2) 25.9 (16.8) 0.0015
APACHE II, score (SD) 18.2 (5.1) 17.1 (5.2) 17.1 (5.7) 0.22
Acute kidney injury, n(%) 47 (34.0) 28 (32.9) 15 (27.3) 0.66
Post-EMR intervention, n(%) 72 (52.2) 61 (71.8) 45 (81.8) 0.0001
Length of stay, days (SD) 11.5 (13.7) 11.2 (11.5) 9.5 (9.3) 0.56
28 day in-hospital mortality, n(%) 18 (13.0) 13 (15.3) 9 (16.4) 0.81
Table 2. Patient demographics and outcomes by appropriateness of vancomycin dose (n=278).
APACHE, acute physiology and chronic health evaluation; EMR, electronic medical record; BMI, body mass index
Figure 2. Pre- and post-intervention vancomycin administration 
and eligible patients for analysis flow diagram.
ICU, intensive care unit
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28-day in-hospital mortality
No1 Yes2
n (%) n (%) p-value3 OR (95% CI) Adjusted OR (95% CI)5
Age, y [SD] 56.0 [17.5] 64.7 [17.1] 0.0040 1.03 (1.01-1.05) 1.03 (1.01-1.06)
Sex
Female 96 (40.3) 10 (25.0) 0.06 1.0 (ref) 1.0 (ref)
Male 142 (59.7) 30 (75.0) 2.03 (0.95-4.34) 2.29 (1.02-5.14)
MRSA
No 213 (89.5) 36 (90.0) 0.92 1.0 (ref) 1.0 (ref)
Yes 25 (10.5) 4 (10.0) 0.95 (0.31-2.89) 0.76 (0.24-2.41)
BMI, kg/m2 [SD] 30.4 [11.8] 28.1 [19.4] 0.47 0.98 (0.94-1.02)
SBP, mmHg [SD] 115.7 [29.3] 113.9 [34.6] 0.73 1.0 (0.99-1.01)
APACHE II, score [SD] 17.4 [5.4] 19.2 [4.4] 0.05 1.07 (1.00-1.14) 1.04 (0.96-1.11)
Acute kidney injury
No 165 (69.3) 23 (57.5) 0.14 1.0 (ref)
Yes 73 (30.7) 17 (42.5) 1.67 (0.84-3.31)
Vasopressors
No 213 (89.5) 33 (82.5) 0.20 1.0 (ref)
Yes 25 (10.5) 7 (17.5) 1.81 (0.72-4.51)
Intubation
No 201 (84.5) 29 (72.5) 0.06 1.0 (ref)
Yes 37 (15.5) 11 (27.5) 2.06 (0.95-4.48)
History of dialysis
No 221 (92.9) 39 (97.5) 0.494 Unable to calc
Yes 17 (7.1) 1 (2.5)
Post-EMR intervention
No 90 (37.8) 10 (25.0) 0.12 1.0 (ref) 1.0 (ref)
Yes 148 (62.2) 30 (75.0) 1.82 (0.85-3.91) 1.72 (0.76-3.88)
Appropriate vancomycin 
dose
Underdosed 120 (50.4) 18 (45.0) 0.81 0.83 (0.38-1.80) 0.60 (0.26-1.41)
Correct 72 (30.3) 13 (32.5) 1.0 (ref) 1.0 (ref)
Overdosed 46 (19.3) 9 (22.5) 1.08 (0.43-2.74) 0.88 (0.33-2.37)
Vancomycin dosing
Total, mean [SD] 1260.5 [384.8] 1212.5 [360.5] 0.46 1.0 (0.999-1.001)
Mg/kg, mean [SD] 15.5 [5.6] 16.6 [5.2] 0.24 1.04 (0.98-1.10)
APACHE, acute physiology and chronic health evaluation; EMR, electronic medical record; BMI, body mass index
Brackets denotes standard deviation. Parenthesis denotes percentage.
1n=238.
2n=40.
3Chi-square test for categorical variables and student’s t-test for continuous variables.
4Fisher’s exact test.
5Model is adjusted for all variables that have an adjusted odds ratio reported.
Table 3. Unadjusted and adjusted odds of 28-day in-hospital mortality among patients receiving vancomycin (n=278) and adjusted odds 
of 28-day in-hospital mortality among those without methicillin-resistant Staphylococcus aureus (MRSA). 
Society of America (IDSA) guidelines increased in the post-
intervention group. Sixty-six percent of patients received a 
dose recommended by the algorithm but outside the IDSA-
recommended vancomycin range because the rounding pushed 
doses inappropriately high for some patients. Even though 
we decreased “traditional” (1 gram) dosing, a button on the 
vancomycin order still permitted easy prescribing of this dose, 
so the rate of traditional dosing still remained over 50%. 
The only clinical predictor that had a significant effect 
on vancomycin dosing in the post-intervention group was 
patient weight. Overweight and obese patients were more 
likely to be underdosed. This occurred even with our analysis 
categorizing overweight and obese patients as receiving the 
“appropriate” dose if they received the maximum 2 gram 
dose even though the calculator recommended a higher 
dose based on their actual body weight. Another factor 
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contributing to underdosing may be the fear of nephrotoxicity. 
A main objective of vancomycin dosing is to achieve 
therapeutic trough levels rapidly. A recent meta-analysis 
reported the incidence of nephrotoxicity between 5% and 
43%, and suggested that the rate is low without concomitant 
administration of other nephrotoxins.18 In our patient 
population, increased patient weights led to unreliable dosing.
The EMR intervention increased the dose of 
vancomycin but failed to have significant effects on clinical 
outcomes. The increased dose in the post-intervention 
group did not have a significant effect on mortality, hospital 
length of stay or increase the risk of acute kidney injury. 
There was a trend towards increased mortality in the post-
intervention group (as reported in a prior study) but this did 
not reach statistical significance.7 
One of the most speculative aspects of our study is the 
association of mortality with a change in drug dosing. A 
prior study suggested that higher vancomycin dosing was 
associated with higher mortality.7 Two interpretations of 
this observation are possible: either sicker patients were 
treated with higher doses (bias), or vancomycin actually 
impairs survival among patients without vancomycin-
treated infection. Interestingly, most reports of increased 
effectiveness of aggressive vancomycin dosing enroll only 
patients with documented vancomycin-susceptible infection 
(e.g., MRSA).8,20 If vancomycin improves survival among 
MRSA patients but harms patients without MRSA, the 
population prevalence of MRSA would be the primary 
determinant of effectiveness in a study. Furthermore, such 
a model would suggest that vancomycin only benefits 
population survival if the local incidence of MRSA exceeds 
a threshold. Although our study does not confirm the 
prior finding, it was not powered to detect a difference in 
mortality.7 The nonsignificant effect estimate, however, 
closely mirrors the effect size of increased mortality with 
higher vancomycin dosing in the previous study. The before-
after methodology of this analysis better limits the potential 
for bias. Based on these data, it is imperative that real time 
diagnostics are developed to avoid exposure to unnecessary 
therapies in critically ill patients. 
Instituting an EMR intervention can significantly decrease 
dosing errors and improve compliance with recommended 
dosing.21 However, EMR interventions can also have 
unintended consequences, including dosing errors. An 
unintended effect of our intervention was that it increased 
the proportion of patients receiving a dose higher than 
recommended. Fortunately, the higher doses did not result 
in an increase in adverse events. In our study, administering 
modestly higher doses did not increase acute kidney injury, 
but inpatient dosing regimens were not characterized. 
LIMITATIONS
Our study has several important limitations. First, 
this was a retrospective data analysis, which introduces 
a risk of bias due to poor documentation or incomplete 
information. We selected variables that would have been 
available at the time of the ED visit and were likely to 
be documented accurately in the EMR. Even with these 
Figure 3. Appropriateness of vancomycin dose by patient weight.
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measures, some relevant factors may not have been 
captured. Second, our study was carried out at a single 
center with a relatively low risk of MRSA. The prevalence 
of MRSA in our study did increase between study periods, 
which is consistent with other reports in the United States.22 
Since the primary outcome was provider behavior, our 
findings are likely valid.6 Third, we used a run-in design 
which excluded a six-month time frame used for education 
for the EMR intervention and a systematic shift to weight-
based dosing. By excluding this time frame we could 
have underestimated early adverse effects of the clinical 
change. Fourth, we were unable to gauge appropriateness 
of the indication for vancomycin in our ED. One study 
evaluated the appropriateness of vancomycin in the ED 
and found that 40% of the patients in the study did not 
warrant vancomycin administration.6 Last, based on the 
recommendations from the IDSA clinical practice guideline 
for the treatment of MRSA, we elected to cap the dose of 
vancomycin at 2 grams for all patients in the intervention 
group.14 Vancomycin pharmacokinetics (volume of 
distribution, protein binding, and clearance) can be altered 
in obese patients; however, the variability does not mean 
that obese patients require higher total daily doses to attain 
target trough concentrations.23-24 
CONCLUSION
In conclusion, the prevalence of therapeutic vancomycin 
dosing (goal 15-20mg/kg actual body weight) did not change 
after the implementation of a decision support system and an 
automated EMR dose calculator. Higher vancomycin dosing 
post-intervention was not associated with acute kidney injury 
or 28-day in-hospital mortality. Additional specific decision-
support interventions (including removing the option to select 
non-recommended dosing) should be explored to further 
increase compliance with accepted guidelines to improve 
antibiotic dosing practices in the ED.
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